Press release
-
Press Release
iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo
BEIJING, May 31, 2026 /PRNewswire/ — iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual…
Read More » -
Press Release
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients…
Read More » -
Press Release
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
CHENGDU, China, May 30, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced today that the results of…
Read More » -
Press Release
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3…
Read More » -
Press Release
Real Estate Expert Justus Smith of Keystone Explains Where Real Estate Commission Dollars Go for HelloNation
KEYSTONE, Fla., May 30, 2026 /PRNewswire/ — When selling a home, where do real estate commission dollars actually go? A HelloNation…
Read More » -
Press Release
MakerWorld’s First User-Initiated Charity Contest Names Winners, Bringing Global Creators’ Goodwill Directly to Cancer Wards
AUGSBURG, Germany, May 30, 2026 /PRNewswire/ — MakerWorld’s first user-initiated charity design contest has completed: winners have now been selected…
Read More » -
Press Release
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
CHENGDU, China, May 29, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced today that at the…
Read More »
